Anupam Rasayan India Limited has signed Letter of Intent worth revenue of $265 million (INR 21,860 million) for next 5 years with one of the leading Japanese Speciality Chemical company to supply new age patented life science active ingredient. The product will be in validation phase for the next eighteen months and upon the successful validation, the supply will commence from calendar year 2025. This product will be manufactured in existing multipurpose manufacturing facilities.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
762.6 INR | -0.10% | -0.03% | -27.51% |
05-21 | Transcript : Anupam Rasayan India Limited, Q4 2024 Earnings Call, May 21, 2024 | |
05-20 | Anupam Rasayan India's Consolidated Net Profit Declines in Fiscal Q4 | MT |
EPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-27.51% | 1B | |
+17.07% | 66.31B | |
-0.29% | 48.46B | |
+21.61% | 43.27B | |
+26.72% | 27.41B | |
+9.25% | 19.26B | |
-2.14% | 16.61B | |
+9.75% | 16.58B | |
-15.01% | 14.41B | |
-30.22% | 14.02B |
- Stock Market
- Equities
- ANURAS Stock
- News Anupam Rasayan India Limited
- Anupam Rasayan India Limited Signs Letter of Intent Worth $265 Million with One of the Leading Japanese Speciality Chemical Company